iZafe Group AB Series B (IZAFE-B) - Total Assets
Based on the latest financial reports, iZafe Group AB Series B (IZAFE-B) holds total assets worth Skr50.56 Million SEK (≈ $5.44 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore iZafe Group AB Series B (IZAFE-B) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
iZafe Group AB Series B - Total Assets Trend (2010–2025)
This chart illustrates how iZafe Group AB Series B's total assets have evolved over time, based on quarterly financial data. See IZAFE-B book value for net asset value and shareholders' equity analysis.
iZafe Group AB Series B - Asset Composition Analysis
Current Asset Composition (December 2025)
iZafe Group AB Series B's total assets of Skr50.56 Million consist of 18.0% current assets and 82.0% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr1.67 Million | 4.7% |
| Accounts Receivable | Skr2.52 Million | 7.1% |
| Inventory | Skr2.23 Million | 6.3% |
| Property, Plant & Equipment | Skr4.42 Million | 12.4% |
| Intangible Assets | Skr24.50 Million | 68.8% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how iZafe Group AB Series B's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of iZafe Group AB Series B.
Key Asset Composition Facts
- Current vs. Non-Current Assets: iZafe Group AB Series B's current assets represent 18.0% of total assets in 2025, an increase from 4.8% in 2010.
- Cash Position: Cash and equivalents constituted 4.7% of total assets in 2025, up from 1.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 68.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 68.8% of total assets.
iZafe Group AB Series B Competitors by Total Assets
Key competitors of iZafe Group AB Series B based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenyang Xingqi Pharmaceutical Co Ltd
SHE:300573
|
China | CN¥2.42 Billion |
|
Hangzhou Alltest Biotech Co. Ltd. A
SHG:688606
|
China | CN¥4.11 Billion |
|
Daxor Corporation
NASDAQ:DXR
|
USA | $35.90 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
iZafe Group AB Series B - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.99 | 0.63 | 0.62 |
| Quick Ratio | 0.81 | 0.38 | 0.49 |
| Cash Ratio | 0.00 | 0.07 | 0.41 |
| Working Capital | Skr-188.00K | Skr-4.08 Million | Skr-7.47 Million |
iZafe Group AB Series B - Advanced Valuation Insights
This section examines the relationship between iZafe Group AB Series B's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.97 |
| Latest Market Cap to Assets Ratio | 0.44 |
| Asset Growth Rate (YoY) | 47.1% |
| Total Assets | Skr35.63 Million |
| Market Capitalization | $15.51 Million USD |
Valuation Analysis
Below Book Valuation: The market values iZafe Group AB Series B's assets below their book value (0.44x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: iZafe Group AB Series B's assets grew by 47.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for iZafe Group AB Series B (2010–2025)
The table below shows the annual total assets of iZafe Group AB Series B from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr35.63 Million ≈ $3.83 Million |
+47.07% |
| 2024-12-31 | Skr24.23 Million ≈ $2.61 Million |
-30.00% |
| 2023-12-31 | Skr34.61 Million ≈ $3.73 Million |
-31.73% |
| 2022-12-31 | Skr50.70 Million ≈ $5.46 Million |
+4.69% |
| 2021-12-31 | Skr48.43 Million ≈ $5.21 Million |
+38.05% |
| 2020-12-31 | Skr35.08 Million ≈ $3.78 Million |
-51.11% |
| 2019-12-31 | Skr71.75 Million ≈ $7.72 Million |
+64.64% |
| 2018-12-31 | Skr43.58 Million ≈ $4.69 Million |
+217.78% |
| 2017-12-31 | Skr13.71 Million ≈ $1.48 Million |
+69.47% |
| 2016-12-31 | Skr8.09 Million ≈ $870.88K |
-34.85% |
| 2015-12-31 | Skr12.42 Million ≈ $1.34 Million |
-17.76% |
| 2014-12-31 | Skr15.10 Million ≈ $1.63 Million |
-11.70% |
| 2013-12-31 | Skr17.11 Million ≈ $1.84 Million |
-29.02% |
| 2012-12-31 | Skr24.10 Million ≈ $2.59 Million |
+577.71% |
| 2011-12-31 | Skr3.56 Million ≈ $382.71K |
-26.87% |
| 2010-12-31 | Skr4.86 Million ≈ $523.30K |
-- |
About iZafe Group AB Series B
iZafe Group AB (publ), a medical technology company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated medication dispenser that handles medication pouches, smart pillboxes, facilitates and enables independent medication, and reminds and alerts in the scheduled doses. It also o… Read more